Business Description
Moberg Pharma AB
NAICS : 325412
ISIN : SE0020353928
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 84.26 | |||||
Equity-to-Asset | 0.98 | |||||
Debt-to-EBITDA | -0.18 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 26.25 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 53.6 | |||||
3-Year EPS without NRI Growth Rate | 41.1 | |||||
3-Year FCF Growth Rate | 41 |
Momentum Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 21.92 | |||||
9-Day RSI | 26.08 | |||||
14-Day RSI | 31.92 | |||||
3-1 Month Momentum % | 41.5 | |||||
6-1 Month Momentum % | -42.69 | |||||
12-1 Month Momentum % | -0.24 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 22.52 | |||||
Quick Ratio | 22.03 | |||||
Cash Ratio | 21.67 | |||||
Days Inventory | 999.05 | |||||
Days Sales Outstanding | 299.2 | |||||
Days Payable | 1059.77 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -105.1 | |||||
Shareholder Yield % | -44.17 |
Profitability Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 73.46 | |||||
Operating Margin % | -288.95 | |||||
Net Margin % | -207.75 | |||||
FCF Margin % | -1315.09 | |||||
ROE % | -2.47 | |||||
ROA % | -2.39 | |||||
ROIC % | -3.47 | |||||
ROC (Joel Greenblatt) % | -496.47 | |||||
ROCE % | -2.94 | |||||
Years of Profitability over Past 10-Year | 6 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Shiller PE Ratio | 0.32 | |||||
PS Ratio | 41.98 | |||||
PB Ratio | 0.49 | |||||
Price-to-Tangible-Book | 1.31 | |||||
EV-to-EBIT | -18.11 | |||||
EV-to-EBITDA | -19.22 | |||||
EV-to-Revenue | 44.89 | |||||
EV-to-FCF | -3.71 | |||||
Price-to-Net-Current-Asset-Value | 1.54 | |||||
Price-to-Net-Cash | 1.6 | |||||
Earnings Yield (Greenblatt) % | -5.52 | |||||
FCF Yield % | -15.82 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:MBGPF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Moberg Pharma AB Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 0.848 | ||
EPS (TTM) ($) | -0.059 | ||
Beta | -0.9 | ||
3-Year Sharpe Ratio | 0.41 | ||
3-Year Sortino Ratio | 0.85 | ||
Volatility % | 194.17 | ||
14-Day RSI | 31.92 | ||
14-Day ATR ($) | 0.135005 | ||
20-Day SMA ($) | 1.442615 | ||
12-1 Month Momentum % | -0.24 | ||
52-Week Range ($) | 0.784 - 4.3 | ||
Shares Outstanding (Mil) | 46.69 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Moberg Pharma AB Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Moberg Pharma AB Stock Events
Event | Date | Price ($) | ||
---|---|---|---|---|
No Event Data |
Moberg Pharma AB Frequently Asked Questions
What is Moberg Pharma AB(MBGPF)'s stock price today?
When is next earnings date of Moberg Pharma AB(MBGPF)?
Does Moberg Pharma AB(MBGPF) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |